Johnson & Johnson began the separation of their consumer healthcare business sector in November 2021. In the split, Johnson & Johnson will retain the Johnson & Johnson name for prescription drugs and medical devices, while the second company will sell consumer health products and take over the Neutrogena, Aveeno, Tylenol, Listerine, Johnson's, Band-Aid and other brands. In September 2022, Johnson & Johnson chose Kenvue as the new name for its Consumer Health business. Kenvue went public through an IPO in May 2023, with Johnson & Johnson maintaining a controlling stake of around 91 percent. On July 24, 2023, Johnson & Johnson launched an exchange offer to split-off Kenvue. Following the completion of the exchange offer, Johnson & Johnson will retain approximately 9.5% of the outstanding shares of Kenvue common stock.
Johnson & Johnson began the separation of their consumer healthcare business sector in November 2021 In the split Johnson & Johnson will retain the Johnson & Johnson name for prescription drugs and medical devices while the second company will sell consumer health products and take over the Neutrogena Aveeno Tylenol Listerine Johnson's Band-Aid and other brands In September 2022 Johnson & Johnson chose Kenvue as the new name for its Consumer Health business Kenvue went public through an IPO in May 2023 with Johnson & Johnson maintaining a controlling stake of around 91 percent On July 24 2023 Johnson & Johnson launched an exchange offer to split-off Kenvue Following the completion of the exchange offer Johnson & Johnson will retain approximately 95% of the outstanding shares of Kenvue common stock